CBD Unlimited Announces Completion of FDA Label Review and Vendor Applications for Entrance into Pharmacy, Food, and Mass Retail

CAVE CREEK, AZ, March 18, 2019 -- CBD Unlimited, Inc., formerly known as Endexx Corporation (EDXC), a provider of innovative phytonutrient-based food and nutritional products, is pleased to announce the completion of its FDA label review for entrance into the pharmacy, food, and mass retail sectors.

Following the completion of its FDA label review, CBD Unlimited submitted vendor applications for mass retail and distribution channels. CBD Unlimited recently disclosed a 20% growth rate from retailers. With the company’s new product labeling, CBD Unlimited expects to be in over 30,000 stores by the end of 2020.

“We are thrilled to complete this stage of our FDA label review as we expand into pharmacy, food, and mass retail centers. Label revisions will be ongoing as the regulations for the hemp industry develop. With our new labeling, we expect to continue expanding across several channels – nationally and internationally,” stated CEO & Chairman, Todd Davis. “As we set up our international distribution hub, we are on-path to expand our cannabidiol (CBD) based products to key international markets.”

With the recent passage of The Farm Bill Act in Dec. 2018, CBD Unlimited is well-positioned to expand its product reach at an exponential rate.

About CBD Unlimited, Inc.

CBD Unlimited, Inc., with its collaborative partners and consultants, develops and distributes two consumable product lines derived from Hemp, which is all-natural and rich in phyto-cannabinoids. Phyto-Bites® is its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation.

The company also has two key technology products and services that launched in 2014. Both products provide essential solutions to promote regulatory compliance and full accountability through asset protection, inventory management, compliance and an “end of sale” technology integration. Based on principles developed by the pharmacological industry, the integrated “Gorilla-Tek” platform is the first standardized hardware agnostic and software solution for tracking high- risk high-shrink regulated and restricted products that maintains compliance with federal, state and local regulations. It is intended to provide conformity with federal and state mandates. Gorilla-Tek™ is also a commercial-grade inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Gorilla-Tek™ increases productivity and reduces costs for retailers, while enhancing their service quality by reducing transaction time for customers.

Websites include: www.cbdunlimited.com, and www.phytobites.com.

Safe Harbor Notice

This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.